FindTrial
Sign In

Construction of a population pharmacokinetic model of teicoplanin in adults and optimization of its dosage regimen

Construction of a population pharmacokinetic model of teicoplanin in adults and optimization of its dosage regimen

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047465
Enrollment
Unknown
Registered
2021-06-19
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-positive bacterial infection

Interventions

Case Series:No

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Greater than 18 years old, male or female; 2.Patients with Gram-positive bacterial infection; 3.Patients treated with teicoplanin for more than 48 hours; 4.At least one steady-state plasma concentration can be obtained.

Exclusion criteria

Exclusion criteria: Patients treated with renal replacement therapy.

Design outcomes

Primary

MeasureTime frame
Plasma concentration;Leukocyte;Neutrophil;C-Reactive Protein;Procalction;Clinical symptoms;Age;Gender;Weight;Height;Renal function;Liver function;—

Countries

China

Contacts

Public ContactYu Xuben

The First Affiliated Hospital of Wenzhou Medical University

yuxuben@126.com+86 13566216906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026